RECRUITINGINTERVENTIONAL
GERD in Children With Cystic Fibrosis
Characteristics of Gastroesophageal Reflux in Children With Cystic Fibrosis
About This Trial
The purpose of this study is to evaluate the prevalence of gastroesophageal reflux disease (GERD) symptoms in pediatric patients with cystic fibrosis using the Gastroesophageal Symptom Assessment Scale (GSAS) and the impact of stopping anti-GERD therapy on the GERD symptoms reported.
Who May Be Eligible (Plain English)
Who May Qualify:
- Children 2-18 years of age with a confirmed CF diagnosis by either a positive sweat test or 2 disease causing CFTR mutations.
- Signed consent
Who Should NOT Join This Trial:
- Declining to participate in the study or sign consent
- History of severe GERD per gastroenterology diagnosis and documentation
- GSAS score \>80
Always talk to your doctor about whether this trial is right for you.
Original Eligibility Criteria
View original clinical language
Inclusion Criteria:
* Children 2-18 years of age with a confirmed CF diagnosis by either a positive sweat test or 2 disease causing CFTR mutations.
* Signed consent
Exclusion Criteria:
* Declining to participate in the study or sign consent
* History of severe GERD per gastroenterology diagnosis and documentation
* GSAS score \>80
Treatments Being Tested
OTHER
Discontinuation of GERD therapy
GERD therapy will be discontinued at time of enrollment.
Locations (1)
Duke University Hospital
Durham, North Carolina, United States